ADAM19: A Novel Target for Metabolic Syndrome in Humans and Mice

• Egile Nagusiak: Lakshini Weerasekera (Egilea), Caroline Rudnicka (Egilea), Qing-Xiang Sang (Egilea), Joanne E. Curran (Egilea), Matthew P. Johnson (Egilea), Eric K. Moses (Egilea), Harald H. H. Göring (Egilea), John Blangero (Egilea), Jana Hricova (Egilea), Markus Schlaich (Egilea), Vance B. Matthews (Egilea)
• Formatua: Liburua
• Argitaratua: Hindawi Limited, 2017-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Obesity is one of the most prevalent metabolic diseases in the Western world and correlates directly with insulin resistance, which may ultimately culminate in type 2 diabetes (T2D). We sought to ascertain whether the human metalloproteinase A Disintegrin and Metalloproteinase 19 (ADAM19) correlates...